ABOUT US
COMMUNITY
ABOUT US>Profile
Company profile
Introducing BICHEDAM's key pipelines,
R&D teams, and their achievements
The Beginning of Bichedam and Innovation
Bichdam Co., Ltd. was founded based on the innovative research of CEO Ho-bin Moon.
During the Ministry of Health and Welfare's Public Resource Development Project for Korean Medicine Treatment Technologies (2017–2019), the blood pressure-lowering effects of the candidate substance BCD101 were confirmed. A patent application for BCD101 was successfully filed in 2019 (Application No. 10-2019-0157657), followed by in-depth research on its key components.
Building on these pioneering achievements, Bichedam Co., Ltd. was officially established in April 2022 with a bold vision: to develop the world’s first medication for nocturnal leg cramps.
Bichedam is
a bio company that researches and develops traditional herbal medicines
using Korea’s rich natural resources, including domestically grown medicinal crops.
We aim to improve human health by combining the benefits of nature with modern science.
At Bichedam
we aim to emerge as a leading company in the global biohealth market.
We present a new paradigm for treating age-related degenerative diseases
through innovative therapies that integrate traditional Korean medicine with modern science and technology.
Bichedam centers its core strategy on the convergence of Korean medicine and modern science, aiming to deliver essential health solutions in an aging society.
Led by a chief Korean medicine practitioner with over 12 years of clinical experience, Bichedam focuses on providing safe and effective natural-based solutions to address the rapidly growing prevalence of age-related degenerative diseases, including cognitive decline, hypertension, and glaucoma.
Led by a chief Korean medicine practitioner with over 12 years of clinical experience, Bichedam focuses on providing safe and effective natural-based solutions to address the rapidly growing prevalence of age-related degenerative diseases, including cognitive decline, hypertension, and glaucoma.
Key Pipeline
| Code | Indications | Research | Non-clinical | Phase 1 | Phase 2 | Phase 3 | Description | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicines | BCD101 | Noturnal leg cramps Rho-kinase inhibitor |
'25 Completion of Phase 1 clinical trial in Korea | ||||||||||
| BCD102 | ISH Combination Therapy Rho-kinase inhibitor |
'26 Clinical IND submission and global technology transfer | |||||||||||
| BCD103 | AD(Dementia) Rho-kinase inhibitor |
||||||||||||
| BCD201 | Non-Alcoholic Steatohepatitis Rho-kinase inhibitor |
Preparing for nonclinical trials | |||||||||||
| BCD202 | Primary Biliary Cirrhosis Rho-kinase inhibitor |
||||||||||||
| Code | Indications | Research | Non-clinical | Human Use | Approval | Release | Description | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Health Supplements | BCD300 | Women's Menopause | Technology Transfer to Helixmith Co., Ltd. Completed |
||||||||||
| BCD301 | Blood Circulation Health | Launching '25 | |||||||||||
| BCD302 | River Health | Launching '26 | |||||||||||
Innovative Medicines
Health Supplements
Development Need
Ⅰ. NLC is common, affecting approximately 40% of adults aged 40 and older, with a high prevalence in the elderly population.
Ⅱ. Blood circulation disorders and cognitive decline frequently occur in patients with chronic diseases,
necessitating the development of products to improve these conditions.
Ⅲ. Nhere are no approved specialized treatments for NCL,
and existing therapeutic approaches have limited efficacy or are difficult to use long-term.
Differentiation
Based on the prospective observational study and safety validation conducted, expansion into an integrated solution for vascular health and leg cramps
Currently, there are no Korean medicine-based treatments in NLC therapy. This multi-mechanism treatment simultaneously targets vascular relaxation, muscle tension relief, and improved sleep quality through a herbal compound prescription.
It enables integrated management of blood circulation and lower limb cramps in the core patient group aged 50-70.
Results of Previous Research
Status of Previous Research
01. Clinical Observational Studies
02. Safety Verification
03. New Drug Development Stages
BCD101: 30 Hypertensive Patients
Prospective Observational Study Completed
01. Clinical Observational Studies
BCD101 Completes Prospective Observational Study in 30 Hypertensive Patients
Blood Pressure Improvement Effects and Safety Verified
Through Korea Institute of Oriental Medicine
02. Safety Verification
Blood Pressure Improvement Effects and Safety Verified Through Korea Institute of Oriental Medicine
Enters Rapid New Drug Development Phase
Based on Clinical Evidence
03. New Drug Development Stages
Enters Rapid New Drug Development Phase Based on Clinical Evidence
Research team
© 2025 BICHEDAM. All Rights Reserved.